<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23255">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718613</url>
  </required_header>
  <id_info>
    <org_study_id>91762</org_study_id>
    <nct_id>NCT01718613</nct_id>
  </id_info>
  <brief_title>Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients</brief_title>
  <acronym>VANCS II</acronym>
  <official_title>Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although arginine vasopressin has been used as an additional drug in refractory shock in
      worldwide clinical practice, there are no prospective studies using it as a first choice
      therapy in patients with cancer and septic shock.

      The aim of this study is assess if the use of arginine vasopressin would be more effective
      on treatment of septic shock in cancer patients than norepinephrine, decreasing the
      composite end point of mortality and organ failure in 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28-day from randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality from all causes in 28-day follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-days mortality</measure>
    <time_frame>90 days after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality from all causes 90 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of mechanical ventilation</measure>
    <time_frame>28 days after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Days alive and free of mechanical ventilation at 28-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of vasopressors</measure>
    <time_frame>28 days after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Days alive and free of any type of vasopressor agent at 28-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of renal replacement therapy</measure>
    <time_frame>28 days after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>requirement of dialysis of hemofiltration at 28-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of organ failure</measure>
    <time_frame>24 hours after ICU admission</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Days alive and free of organ failure according the sequential organ failure assessment (SOFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of organ failure</measure>
    <time_frame>96 hours after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Days alive and free of organ failure according to sequential organ failure assessment (SOFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>Hospital discharge</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement</description>
    <arm_group_label>Vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement</description>
    <arm_group_label>Norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid neoplasm needing ICU

          -  Septic Shock according standard criteria

        Exclusion Criteria:

          -  Younger than 18 years;

          -  Pregnancy;

          -  Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;

          -  Severe hyponatremia (Na&lt;130mEq/L);

          -  Acute mesenteric ischemia;

          -  Acute myocardial infarction;

          -  Cardiogenic shock;

          -  Current use of vasopressor before randomization

          -  Expected ICU stay less than 24 hours

          -  Enrolled in another study;

          -  Refusal to consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiane M Zambolim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia and Critical Care, Intensive Care Unit - ICESP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristiane M Zambolim, MD</last_name>
    <phone>+11-55-3893-3267</phone>
    <email>czambolim@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludhmila A Hajjar, MD, PhD</last_name>
    <phone>+11-55-3893-3267</phone>
    <email>ludhmila@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>Sao Paulo/SP</state>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiane M Zambolim, MD</last_name>
      <phone>+55-11-38933267</phone>
      <email>czambolim@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Cristiane M Zambolim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 2, 2012</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Cancer do Estado de São Paulo</investigator_affiliation>
    <investigator_full_name>Cristiane Maciel Zambolim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
